IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)

IncobotulinumtoxinA has not produced a single case of antibody-induced therapy failure after 8 years of worldwide usage. We are reporting a patient with progressive hereditary juvenile onset generalised dystonia who was pretreated with abobotulinumtoxinA for 15 years, before she received incobotulin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neural Transmission 2014-07, Vol.121 (7), p.769-771
Main Authors: Dressler, Dirk, Adib Saberi, Fereshte, Bigalke, Hans
Format: Article
Language:English
Subjects:
Acetylcholine Release Inhibitors - therapeutic use
Botulinum Toxins, Type A - therapeutic use
Dystonic Disorders - drug therapy
Female
Humans
Medicine
Medicine & Public Health
Middle Aged
Neurology
Neurology and Preclinical Neurological Studies - Short communication
Neurosciences
Psychiatry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IncobotulinumtoxinA has not produced a single case of antibody-induced therapy failure after 8 years of worldwide usage. We are reporting a patient with progressive hereditary juvenile onset generalised dystonia who was pretreated with abobotulinumtoxinA for 15 years, before she received incobotulinumtoxinA. To the fifth and sixth applications, she responded with complete therapy failure. Mouse hemidiaphragm assay testing revealed a maximal botulinum toxin antibody titre. Improved specific biological activity and lack of complexing proteins seem to reduce the antigenicity of incobotulinumtoxinA. However, this first ever report indicates that it does not eliminate it entirely.
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-014-1165-7